Oxford BioDynamics (LON:OBD) Shares Down 2.6% – What’s Next?

Shares of Oxford BioDynamics Plc (LON:OBD – Get Free Report) dropped 2.6% on Tuesday. The company traded as low as GBX 0.10 and last traded at GBX 0.11. 168,821,188 shares traded hands during mid-day trading, an increase of 387% from the average session volume of 34,695,418 shares. The stock had previously closed at GBX 0.12.

Oxford BioDynamics Trading Down 2.6%

The company has a current ratio of 2.01, a quick ratio of 2.80 and a debt-to-equity ratio of 131.61. The stock has a market cap of £15.05 million, a P/E ratio of -0.56 and a beta of 0.42. The firm’s 50-day simple moving average is GBX 0.11 and its 200 day simple moving average is GBX 0.17.

Oxford BioDynamics Company Profile

(Get Free Report)

Oxford BioDynamics Plc is a global biotechnology company, advancing personalized healthcare by developing and commercializing precision medicine tests for life-changing diseases. Its flagship product is EpiSwitch® CiRT (Checkpoint Inhibitor Response Test) for cancer, a predictive immune response profile for immuno-oncology (IO) checkpoint inhibitor treatments, launched in February 2022. In March 2021, the Company launched its first commercial prognostic test, EpiSwitch® CST (Covid Severity Test) and the first commercially available microarray kit for high-resolution 3D genome profiling and biomarker discovery, EpiSwitch® Explorer Array Kit.

Recommended Stories

Receive News & Ratings for Oxford BioDynamics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford BioDynamics and related companies with MarketBeat.com's FREE daily email newsletter.